In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Apellis nets $131.8mm via follow-on

Executive Summary

In its first post-IPO financing, Apellis Pharmaceuticals Inc. (developing therapies that inhibit the complement system) netted $131.8mm through a follow-on public offering of 5.5mm common shares at $25.50 each. The company has earmarked the funds for ongoing and future clinical trials of APL2 in patients with geographic atrophy, wet age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria; and for development of new candidates.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies